SkinBioTherapeutics PLC SBTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX 9.75
- Day Range
- GBX 9.57–9.99
- 52-Week Range
- GBX 7.00–29.50
- Bid/Ask
- GBX 9.50 / GBX 10.00
- Market Cap
- GBX 1.98 Bil
- Volume/Avg
- 32,119 / 767,775
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 105.41
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
SkinBioTherapeutics PLC is a life science company focused on skin health. It is focused on the development of technology to protect, manage, and restore skin utilizing proteins found in the human microbiota. It is targeting three specific skin healthcare sectors; cosmetics, infection control, and eczema.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 11
Valuation
|
Metric
|
SBTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.08 |
Price/Sales | 105.41 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SBTX
|
|---|---|
Quick Ratio | 6.48 |
Current Ratio | 6.57 |
Interest Coverage | −380.12 |
Quick Ratio
SBTX
Profitability
|
Metric
|
SBTX
|
|---|---|
Return on Assets (Normalized) | −97.92% |
Return on Equity (Normalized) | −125.55% |
Return on Invested Capital (Normalized) | −119.85% |
Return on Assets
SBTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Cddbxgh | Cprmrw | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Crbtrbcv | Ktvmbk | $114.2 Bil | |||
| Moderna Inc
MRNA
| Cxbchtjg | Thcz | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Whkgpkjt | Hjyb | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Xhzfnrwl | Hdmzj | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Shzqbmvgx | Qxmspx | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Gtylttkwc | Fmmchwn | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Frskwxhfm | Yjvsg | $12.8 Bil | |||
| Incyte Corp
INCY
| Wqbrqjqz | Bcvgt | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Hhznjrgln | Qyyhxk | $12.2 Bil |